Status:
RECRUITING
Delivery Optimization for Pre-Exposure Prophylaxis (DO PrEP) Study
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Bill and Melinda Gates Foundation
Conditions:
HIV
Human Immunodeficiency Virus
Eligibility:
All Genders
16-30 years
Phase:
NA
Brief Summary
The overall goal is to determine whether an end-to-end decentralized delivery service for PrEP is more effective, safe, acceptable, and cost-effective than facility-based PrEP delivery.
Detailed Description
Optimizing pre-exposure prophylaxis (PrEP) delivery with a focus on priority populations is critical to realize the enormous potential of PrEP for HIV prevention. HIV incidence remains relentlessly hi...
Eligibility Criteria
Inclusion
- Aged 16 years - 30 years old,
- Men in serodifferent relationships or those reporting male to male sex,
- Heterosexual cis-gender females
- Interested in use of PrEP for HIV prevention
- Able and willing to provide informed consent for study procedures
Exclusion
- HIV infection based on negative HIV rapid tests
- Clinically ineligible for PrEP
- The participant doesn't reside in the study community for the duration of follow-up
Key Trial Info
Start Date :
July 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT06176859
Start Date
July 17 2023
End Date
May 1 2026
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Human Sciences Research Council
Durban, KwaZulu-Natal, South Africa